CARCINOMA, SQUAMOUS CELL

This study tests an experimental drug called N17350 for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumor lesions every two weeks for up to 12 weeks. Researchers aim to find the safest and most effective dos…

This early-phase study tests a new three-drug combination (zanzalintinib, pembrolizumab, and cetuximab) in adults with recurrent or metastatic head and neck cancer that cannot be cured by local treatments. The main goal is to find the safest dose and check for early signs of tumo…

This study tests a combination of two drugs, lenvatinib and pembrolizumab, in people with advanced anal or rectal cancer that has spread and no longer responds to standard chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease. About 35 participa…

This study tests a new drug, NBTXR3, that is injected directly into tumors and activated by radiation. It is for patients aged 60 and older with advanced head and neck cancer who cannot receive standard chemotherapy. The goal is to see if adding NBTXR3 to radiation therapy helps …

This study looks at a blood test that measures tiny bits of tumor DNA floating in the bloodstream. Researchers will enroll 50 adults with head and neck cancer who are scheduled for surgery. They want to see how these DNA levels change after surgery and whether they can help predi…

This study follows 220 people with HPV-related throat cancer to see if a simple blood test for HPV DNA and changes in two genes (TRAF3 and CYLD) can predict if the cancer will come back after treatment. Participants will give blood samples and fill out quality-of-life questionnai…

This study looks at whether a feature called tumor budding can guide doctors in deciding if lymph node removal in the neck is necessary for early-stage oral cancer. About 524 patients will be followed for five years to compare survival and quality of life between those who get st…